The objectives were to determine the influence of oxcarbazepine (OXC) monotherapy on the serum levels of total homocysteine (tHcy), vitamin B12 and folate in patient with epilepsy pooling together casecontrol or interventional studies. A comprehensive literature search was done through four databases including MEDLINE/PubMed, Scopus, Embase and Web of Science from January 2000 to February 2016. A random effects model (the DerSimonian-Laird estimator) was utilized to pool the effect sizes of the individual studies. The between-study variance was assessed using the Q2 test (significance level p < 0.1) and quantified using the I 2 test (>50% indicated evidence of heterogeneity). Overall, six studies found eligible for inclusion. The meta-analysis for tHcy revealed that the serum level of tHcy was no significant difference between patient on OXC monotherapy and healthy people [mean difference (MD) 0.31; 95% CI À1.05, 1.67, p = 0.653]. The meta-analysis for vitamin B12 [MD À46.51; 95% CI À113.63, 20.62, p = 0.174] and folate [MD À0.48; 95% CI À1.06, 0.11, p = 0.113] indicated that there was no significant difference between patients on OXC monotherapy and healthy people. In conclusion, the meta-analysis does not support the hypotheses that OXC monotherapy changes the serum levels of tHcy, vitamin B12 and folate.
Introduction
Epilepsy is one of the most prevalent neurological disorders in the world, affecting approximately 50 million people worldwide [1] . Globally, an estimated of 2.4 million people are diagnosed with epilepsy each year. According to the World Health Organization (WHO) report, the incidence of epilepsy in high-income countries are between 30 and 50 per 100,000 people in the general population and in low-and middle-income countries, this statistic can be up to two times higher [1] .
According to the contemporary proposal by the International League Against Epilepsy (ILAE), epilepsy is defined by any of the following conditions: (a) at least two unprovoked (or reflex) seizures occurring >24 h apart; (b) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the following 10 years; (c) diagnosis of an epilepsy syndrome [2] .
Epilepsy is a chronic condition that requires long term treatment with antiepileptic drugs (AEDs) [3] . Oxcarbazepine (OXC), is one of the newer antiepileptic drugs used as both monotherapy and adjunctive therapy for the treatment of partial seizures with or without secondary generalization [4] . Moreover, it is effective for treatment of the Trigeminal neuralgia as well [5] . Earlier studies have depicted that cardiovascular diseases (CVD) among epileptic patients are higher than healthy people [6, 7] . One of the leading risk factors for CVD in these patients is using AEDs [8, 9] . It is suggested that AEDs changes the levels of many biomarkers that are concomitant with developing atherosclerosis including altered lipid profile as increasing total cholesterol and low density lipoprotein [10] [11] [12] , increasing serum levels of homocysteine [13] and C-reactive protein (CRP) [9] .
Homocysteine (Hcy) is formed as an intermediate product during the metabolism of methionine to cysteine. For converting Hcy to methionine (re-methylation pathway) vitamin B12 and folic acid as cofactors are required [14, 15] . The absence of these cofactors, as well as vitamin B6 (trans-sulfuration pathway) leads to hyperhomocysteinemia [16] . Several studies revealed that older AEDs increase tHcy and reduce the serum levels of folate, vitamin B6 and B12 [17] [18] [19] [20] . However, for the newer AEDs including OXC, the association between using these drugs and the serum levels of tHcy and its cofactors on cardiovascular diseases is controversial [21, 22] . Therefore, the aim of this systematic review and metaanalysis was to find the association between using OXC and tHcy, vitamin B9 and B12.
Methods
The investigators performed the systematic review and metaanalysis according to the PRISMA protocol [23] . This study was registered in PROSPERO with registration number: CRD42015029570.
Literature searches
A comprehensive literature search was done and four foremost databases namely MEDLINE/PubMed, Scopus, Web of Science (WOS) and Embase were searched for papers published from January 2000 to February 2016 by two autonomous investigators (SR and AA). The following key words were used; epilepsy; oxcarbazepine; trileptal; homocysteine; Hcy; "vitamin B12"; "vit B12"; cobalamin; folate; "folic acid"; "vitamin B9"; "vit B9"; "vitamin M"; "vit M"; "pteroylglutamic acid". In PubMed and Embase for each keyword Medical Subject Heading (MeSH) and EMTREE databases were used; respectively. Based on each database search strategy was adjusted. Details of search strategy in all four databases; which mentioned above are available in the Supplementary part of this paper (Supp. Tables 1, 2, 3 & 4) .
To supplement the searches and ensure optimal and complete literature retrieval, Google scholar and the grey literature databases including Dissertations & Theses database of Proquest, clinicaltrials.gov and OpenGrey (system information on Grey literature in Europe) were also searched. Additionally, a manual check of the reference lists of all enrolled papers and pertinent systematic review and metaanalysis was accomplished.
Literature search results were downloaded into EndNote (version X7), for Windows, Thomson Reuters, Philadelphia, PA, USA, (Release date: 30 September 2014) to merge retrieved citations, eliminate duplications and to facilitate the review process.
Eligibility criteria
Relevant studies were included if they fulfilled the following criteria: (1) case-control studies measured the levels of tHcy, vitamin B12 or folate, (2) interventional studies investigating to determine the influence of OXC monotherapy on the serum levels of tHcy, vitamin B12 or folate, (3) article was published in English, (4) the apparently healthy control group. Articles were excluded if they: (1) applied study design rather than case-control or interventional studies, (2) were animal or in vitro studies, (3) were studies rather than original article or article in press, (4) were studies without control group or absence of healthy control group, (5) did not report any of the serum levels of the tHcy, vitamin B12 or folate, (6) did not mention the influence of OXC as monotherapy.
Study selection and data extraction
Titles and abstracts of all articles retrieved in the initial search were evaluated independently by two reviewers (SR and AA). Then full texts of included papers were assessed and papers that did not meet the above criteria were discarded. Any disagreements were discussed and resolved by consensus.
The following data were extracted from the included papers: Title, first author, year of publication, country, sample size, age, sex, study design, mean and standard deviation (SD) for serum homocysteine, vitamin B12 and folate.
Data analysis
To calculate the overall effect size, a mean difference (MD) for homocysteine, vitamin B12 and folate separately was calculated and then pooled by the generic inverse variance method by the user written "metan" command in Stata software (version 12). Effect size was pooled from all eligible studies using the DerSimonian-Laird random effects model (REM) for meta-analysis. This model was preferred to a fixed effect model, since it is based on the assumption that a distribution of effects exists, resulting in heterogeneity among study results. Results are presented in tables and forest plots where MD and 95% confidential intervals (95% CI) are figured out for every study inserted in the model and for the overall estimate. Heterogeneity was assessed using I 2 statistic provided the relative amount of variance of the summary effect. In analyses if heterogeneity was observed, we explored possible sources of heterogeneity by sub-group analyses based on age of participants.
To retrieve the extent of publication bias, Egger's test and Begg's test were computed with the user written "metabias" command in Stata (version 12) software. All statistical analyses were done by using Stata version 12 (StataCorp, College Station, Texas, USA).
Results

Study selection
The literature search identified 175 potential papers for inclusion in the study, 19 records from PubMed, 70 records from Scopus, 17 records from WOS and 69 records from Embase. Among them, 92 were duplicate and discarded. Following abstract screening, 79 papers excluded since they were review, consensus, guideline and case report. Thirteen papers remained for detailed full-text evaluation based on inclusion criteria. In the next step, full text of the remaining papers screened precisely and among them nine papers discarded [22, [24] [25] [26] [27] [28] [29] [30] [31] . For those articles which have no basic data for the analysis, we requested the corresponding author via email; however, none of them responded. Therefore, four papers enrolled to this study through searching in these databases. Moreover, searching Google scholar manually resulted in two new conference papers [32, 33] . Subsequently, six records included for the meta-analysis [21, [32] [33] [34] [35] [36] (Fig. 1) . The articles that were included in our analysis are shown in Table 1 .
Study characteristics
Among included papers, four papers [21, 32, 35, 36] had the serum levels of all three parameters of this study namely; tHcy, vitamin B12 and folate and one of them had levels of vitamin B12 and folate [34] and the last one had solely level of vitamin B12 [33] . All the included studies were case-control and measured the serum levels of tHcy, vitamin B12 and folate in healthy people and patients on OXC monotherapy more than 6 months, except one study that did not mention the precise time for patients on OXC therapy [34] . Among the included papers, three of them indicated that study participants were free from any comorbidities including history of cardiac or peripheral vascular disease, and renal, hepatic, or thyroid disease and were not on any medications or supplements [21, 35, 36] .
Meta-analysis
Homocysteine
Four studies included for meta-analysis. The overall pooled MD of 0.31 (95% CI: À1.05, 1.67) and P value of 0.653, indicate that the serum levels of tHcy did not differ significantly between 74 cases and 94 healthy control subjects (Fig. 2) . There was no heterogeneity found between studies (I-squared = 0.0%, p = 0.631). Egger's test showed no publication bias (Egger test, P = 0.6).
Vitamin B12
Six studies included for meta-analysis. The overall pooled MD of À46.51 (95% CI: À113.63, 20.62) and P value of 0.174 indicate that the serum levels of vitamin B12 did not differ significantly between 189 cases and 310 healthy control subjects. Statistically significant heterogeneity was found among these studies (I-squared = 55.7% and p = 0.046) (Fig. 3) . Egger's test showed no publication bias (Egger test, p = 0.326).
Folate
Five studies included for meta-analysis. The overall pooled MD of À0.48 (95% CI: À1.06, 0.11) and P value of 0.113 indicate that the serum levels of vitamin B12 did not differ significantly between 170 cases and 294 healthy control subjects. There was no heterogeneity found among studies (I-squared = 0.0%, p = 0.444) (Fig. 4) . Egger's test showed no publication bias (Egger test, p = 0.191).
Subgroup analysis
In subgroup analysis by age [1-18 and >18 years], there was no significant difference between two groups in all three parameters (P > 0.05). However, the heterogeneity remain significant after subgroup analysis in vitamin B12 (1-18 years, I-squared = 38.3%, p = 0.182; >18 years, I-squared = 78.8%, p = 0.030) ( Table 2 ).
Discussion
In response to the question of this review that "How does oxcarbazepine influence on the serum levels of total homocysteine, vitamin B12 and folate?", the results of this systematic review and meta-analysis depicted OXC does not have any significant influence on the tHcy level and its metabolism cofactors, vitamin B12 and folate as well.
Hcy is a thiol-containing amino acid that is formed following breakdown of amino acid methionine [37] . High level of tHcy leads to several disadvantageous effects on the body [38] . For intercepting cytotoxic accumulation of Hcy, cells convert it to its non-cytotoxic metabolites. Two pathways are available for homocysteine metabolism, re-methylation and trans-sulfuration. Vitamin B12 and folate are cofactors for re-methylation pathway and vitamin B6 for trans-sulfuration pathway. As a result, sufficient amount of these vitamins is essential for maintaining homocysteine homeostasis. Lacks of these cofactors disrupt this homeostasis and leads to hyperhomocysteinemia [39] .
Hyperhomocysteinemia is an dominant probable risk factor for several disorders including coronary artery disease [40] [41] [42] [43] , stroke [44] [45] [46] [47] [48] , carotid artery stenosis [49] [50] [51] , heart failure [52] , venous thromboembolic disease [53] [54] [55] [56] , osteoporosis [57] [58] [59] , Alzheimer disease [60, 61] , dementia [60] and neural-tube defects [62] . Several mechanisms were suggested for developing atherosclerosis due to hyperhomocysteinemia, (a) Free radicals generation during the oxidation of homocysteine may directly injure endothelial cells especially hydrogen peroxide [63] [64] [65] . (b) Decline nitric oxide (NO) bioavailability, consequently progress deleterious effects that are concomitant with diminishing of NO including vasoconstriction, smooth muscle proliferation, increase platelet activation and leucocyte recruitment [63, 66] . (c) Inhibit glutathione peroxidase activity [16] . (d) Enhance the production of several pro-inflammatory cytokines [67] . (e) Develop lipid peroxidation [68] . (f) Promotes oxidative modification of low-density lipoproteins [63] . Moreover, previous studies in animal model indicated that hyperhomocysteinemia could enhance seizure activity and as well leads to antiepileptic drug resistance [69] [70] [71] .
OXC is one of the newer and common AEDs that prescribed for the treatment of partial seizures. OXC is the 10-keto-analogue of carbamazepine with fewer adverse effects [72] . Effect of OXC on serum level of tHcy was controversial and some papers depicted OXC increase level of serum tHcy [26, 34, 73] and some papers did not show this effect [21, 35] .
Earlier studies revealed older AEDs as carbamazepine and valproate increase tHcy and attenuate serum levels of vitamin B12 and folate [17, 18] . In a study by Ni et al., to determine how valproate could effect on the serum level of tHcy, patients with epilepsy on valproate have higher levels of tHcy in comparison to healthy subjects [18] . On the other hand, a study by Gorjipour et al., showed that the serum level of tHcy in patient on CBZ were significantly higher than healthy control subjects. The serum level of folate was significantly lower in cases on CBZ than healthy control group nonetheless CBZ did not have any significant effect on vitamin B12 level. Results of analysis for patients on valproate exhibited that valproate similar to CBZ increase tHcy level significantly; however, valproate does not have any effect on folate. Results of this study for vitamin B12 in patients on valproate is debatable since the results of the vitamin B12 in the context of the paper is in contrast as in the table of this study, they indicated in the context that valproate decrease vitamin B12 significantly; though, in the table of this paper data displayed valproate increase the serum level of vitamin B12 significantly [17] .
Results of the current study revealed that the pooled MD serum level of tHcy is higher in cases treated with OXC monotherapy than control group even though p-value of 0.346, displayed OXC does not have any significant effect on tHcy. The pooled MD of serum vitamin B12 and folate are higher in control group than cases treated with OXY group nevertheless this effect is not significant for vitamin B12 (p = 0.562) and folate (p = 0.113) as well. The main reason for this difference between carbamazepine and its Table 1 Summary of studies included in the meta-analysis. In both studies the study populations were children; however, the mean AE SD for age did not mentioned. derivative oxcarbazepine which both are categorized in P450-inducing AEDs is the enzyme-inducing effect of OXC is lower than the carbamazepine [74] [75] [76] . Earlier studies revealed that oxcarbazepine is an inducer of cytochrome P450 system [77] . It was shown that effect of OXC was dose-dependent and it had been found to induce hepatic enzymes when given at high doses to adult patients [78, 79] .
Albeit, folate and vitamin B12 considered as main probable mechanism for increasing tHcy; however, because of the vital role of these vitamins in body, reduction of them are associated with miscellaneous types of diseases which both or any of them are involved including anemia [80, 81] , cognitive decline and impairment [82] , osteoporosis [83, 84] , cancer [85, 86] , psychiatric disease [82] and congenital malformations [87] . various mechanisms for attenuation of the level of folate and vitamin B12 in patients on AEDs have been proposed: (a) impairment of folate and vitamin B12 absorption, (b) as folate is cofactor for several cytochrome P450 enzymes reactions, induction of liver microsomal enzymes by prolong use of AEDs increase folate metabolism and consequently increase folate demands that eventually leads to folate depletion [88] [89] [90] [91] .
Subgroup analysis of age for vitamin B12 revealed that vitamin B12 level was lower in children [MD À62.39; 95% CI À135.01, 10.24] than adult [MD À7.59; 95% CI À46. 91, 31.73] . Previous studies depicted that activity of cytochrome P450 system was higher in children than adults. This is due to the fact that OXC is an inducer of CYP450 system, hence, it could accelerate attenuation of the serum levels of vitamin B12 in children more than adults [92] . Moreover, differences in the dose of OXC in the included papers could be another reason for this difference. However, the dose of the OXC did not mention in the included papers.
There are some limitations in this study that should need to be recognized. First, the number of the included studies in our metaanalysis was relatively limited. Second, OXC dose did not mention due to lack of reports in several included studies. Third, some other confounding factors were unable to be taken into consideration due to the absence of the data in the included papers, such as other atherogenic parameters including lipid profiles. The strength of the study was a comprehensive search that was done which all the vital databases namely, MEDLINE/PubMed, Scopus, Web of Science and Embase were searched and as well Google scholar and some grey literature databases were search manually for possible studies from other literature sources. The other property was, merely studies were included that assessed OXC as monotherapy and did not have any comorbidity disorders. Abbreviation: OXC, oxcarbazepine.
Conclusion
In conclusion, this meta-analysis does not support the hypothesis that OXC monotherapy changes the serum levels of tHcy, vitamin B12 and folate. It seems that OXC can be prescribed with less concern than older AEDs as carbamazepine and valproate in developing atherosclerosis or other disorders that are concomitant with elevated tHcy and declined vitamin B12 and folate.
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